Targeted Radioimmunotherapy and Theranostics with Alpha Emitters

Area of Science:

• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radiolabeled antibodies enable targeted cancer cell radiation delivery.
• Both alpha- and beta-emitting radioisotopes can be utilized.
• Radionuclide selection depends on antibody biodistribution and half-life.

Purpose of the Study:

• To review the current status of radioimmunotargeted agents in oncology.
• To highlight novel strategies for enhanced cancer targeting.

Main Methods:

• Review of existing literature on radioimmunotherapy.
• Discussion of antibody fragments (minibodies, diabodies), bispecific antibodies, and pretargeting strategies.
• Examination of bioorthogonal click chemistry in targeting.

Main Results:

• Alpha-emitters offer high-energy, short-range radiation, sparing normal tissues.
• Whole antibodies have limitations due to long clearance times and radiation exposure.
• Novel approaches demonstrate potential for improved therapeutic efficacy and safety.

Conclusions:

• Smaller antibody fragments and advanced targeting methods offer improved biological clearance.
• Engineered bispecific antibodies and pretargeting strategies are promising for radioimmunotherapy.
• Ongoing research into novel targets is advancing the field of targeted cancer radiation therapy.